{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:58:24Z","timestamp":1794621504465,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jocn.2026.111905","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:16:05Z","timestamp":1770761765000},"page":"111905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["GLP-1 receptor agonists and aneurysm rupture risk in type 2 diabetes: a multicenter retrospective study"],"prefix":"10.1016","volume":"147","author":[{"given":"Sean Y.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Sonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ben-Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Bowles Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jocn.2026.111905_b0005","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1161\/STR.0000000000000070","article-title":"Guidelines for the management of patients with unruptured intracranial aneurysms","volume":"46","author":"Thompson","year":"2015","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.jocn.2026.111905_b0010","first-page":"141","article-title":"An overview of intracranial aneurysms","volume":"9","author":"Keedy","year":"2006","journal-title":"Mcgill J Med"},{"issue":"1","key":"10.1016\/j.jocn.2026.111905_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jocn.2009.04.010","article-title":"Risk of growth in unruptured intracranial aneurysms: a retrospective analysis","volume":"17","author":"So","year":"2010","journal-title":"J Clin Neurosci"},{"issue":"5","key":"10.1016\/j.jocn.2026.111905_b0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.2008.169573","article-title":"Characteristic features of unruptured intracranial aneurysms: predictive risk factors for aneurysm rupture","volume":"81","author":"You","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.jocn.2026.111905_b0025","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/STROKEAHA.117.017391","article-title":"PHASES score for the Management of Intracranial Aneurysm","volume":"48","author":"Bijlenga","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2026.111905_b0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.biochi.2018.06.026","article-title":"Glucagon-like peptide-1: a new therapeutic target to treat abdominal aortic aneurysm?","volume":"152","author":"Raffort","year":"2018","journal-title":"Biochimie"},{"issue":"9","key":"10.1016\/j.jocn.2026.111905_b0035","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00595-015-1287-z","article-title":"Glucagon-like peptide-1 prevented abdominal aortic aneurysm development in rats","volume":"46","author":"Yu","year":"2016","journal-title":"Surg Today"},{"issue":"4","key":"10.1016\/j.jocn.2026.111905_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121077","article-title":"Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice","volume":"10","author":"Lu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jocn.2026.111905_b0045","doi-asserted-by":"crossref","unstructured":"Pasi M, Bretonni\u00e8re A, Lochon L, et al. Glucagon-like peptide-1 receptor agonists and risk of nontraumatic intracerebral hemorrhage in patients with type 2 Diabetes. stroke. Published online June 5, 2025. doi:10.1161\/STROKEAHA.125.050972.","DOI":"10.1161\/STROKEAHA.125.050972"},{"issue":"9596","key":"10.1016\/j.jocn.2026.111905_b0050","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2026.111905_b0055","unstructured":"Malin B. Summary of the assessment of trinetx data privacy principles through an empirical analysis."},{"issue":"1","key":"10.1016\/j.jocn.2026.111905_b0060","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70093","article-title":"With big data comes big responsibility: strategies for utilizing aggregated, standardized, de-identified electronic health record data for research","volume":"18","author":"Olaker","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.jocn.2026.111905_b0065","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7326\/M23-1490","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the american college of physicians","volume":"177","author":"Drake","year":"2024","journal-title":"Ann Intern Med"},{"issue":"35","key":"10.1016\/j.jocn.2026.111905_b0070","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Marsico","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jocn.2026.111905_b0075","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/STROKEAHA.119.027557","article-title":"Glucagon-like peptide-1 receptor agonists and prevention of stroke systematic review of cardiovascular outcome trials with meta-analysis","volume":"51","author":"Bellastella","year":"2020","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.jocn.2026.111905_b0080","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"4","key":"10.1016\/j.jocn.2026.111905_b0085","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.jocn.2026.111905_b0090","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-022-01686-3","article-title":"Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms","volume":"21","author":"Verg\u00e8s","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jocn.2026.111905_b0095","doi-asserted-by":"crossref","unstructured":"Chaudhuri A, Ghanim H, Vora M, et al. Exenatide Exerts a Potent Antiinflammatory Effect. Accessed August 13, 2025. https:\/\/dx.doi.org\/10.1210\/jc.2011-1508.","DOI":"10.1210\/jc.2011-1508"},{"key":"10.1016\/j.jocn.2026.111905_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"issue":"17","key":"10.1016\/j.jocn.2026.111905_b0105","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jocn.2026.111905_bib196","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","article-title":"Glucagon-like peptide-1 receptor action in the vasculature","volume":"111","author":"Almutairi","year":"2019","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.jocn.2026.111905_bib197","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"24","key":"10.1016\/j.jocn.2026.111905_b0110","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1161\/CIRCULATIONAHA.107.728303","article-title":"NF-\u03baB is a key mediator of cerebral aneurysm formation","volume":"116","author":"Aoki","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jocn.2026.111905_b0115","doi-asserted-by":"crossref","first-page":"21375","DOI":"10.1038\/s41598-022-25855-2","article-title":"Canonical NF-\u03baB signaling pathway and GRO-\u03b1\/CXCR2 axis are activated in unruptured intracranial aneurysm patients","volume":"12","author":"Kami\u0144ska","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jocn.2026.111905_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2021.11869","article-title":"Involvement of TLR2\/4\u2011MyD88\u2011NF\u2011\u03baB signaling pathway in the pathogenesis of intracranial aneurysm","volume":"23","author":"Zhang","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jocn.2026.111905_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117294","article-title":"Roles of inflammation in the natural history of intracranial saccular aneurysms","volume":"424","author":"Wang","year":"2021","journal-title":"J Neurol Sci"},{"issue":"9","key":"10.1016\/j.jocn.2026.111905_b0135","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/jcbfm.2012.84","article-title":"Biology of intracranial aneurysms: role of inflammation","volume":"32","author":"Chalouhi","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"issue":"9","key":"10.1016\/j.jocn.2026.111905_b0140","article-title":"Prospective randomized open-label trial to evaluate risk factor management in patients with unruptured intracranial aneurysms: study protocol","volume":"13","author":"Md","year":"2018","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jocn.2026.111905_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106949","article-title":"Aspirin and growth, rupture of unruptured intracranial aneurysms: a systematic review and meta-analysis","volume":"209","author":"Guo","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"10.1016\/j.jocn.2026.111905_b0150","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1161\/HYPERTENSIONAHA.122.18970","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors on the rupture risk among hypertensive patients with intracranial aneurysms","volume":"79","author":"Zhong","year":"2022","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.jocn.2026.111905_b0155","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2176\/nmc.oa.2021-0017","article-title":"Small unruptured aneurysm verification-prevention effect against growth of cerebral aneurysm study using statin","volume":"61","author":"Yoshida","year":"2021","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"2","key":"10.1016\/j.jocn.2026.111905_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246865","article-title":"Candidate drugs for preventive treatment of unruptured intracranial aneurysms: a cross-sectional study","volume":"16","author":"Shimizu","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jocn.2026.111905_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247153","article-title":"Effect of combined acetylsalicylic acid and statins treatment on intracranial aneurysm rupture","volume":"16","author":"Terce\u00f1o","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jocn.2026.111905_b0170","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s10143-020-01420-1","article-title":"Radiological surveillance of small unruptured intracranial aneurysms: a systematic review, meta-analysis, and meta-regression of 8428 aneurysms","volume":"44","author":"Lee","year":"2021","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.jocn.2026.111905_b0175","doi-asserted-by":"crossref","unstructured":"Feghali J, Ruchika F, Horowitz MA, et al. Glucagon-like peptide-1 receptor agonists and decreased subarachnoid hemorrhage risk in patients with intracranial aneurysm. Stroke. Published online January 6, 2026. doi:10.1161\/STROKEAHA.125.053599.","DOI":"10.1161\/STROKEAHA.125.053599"},{"key":"10.1016\/j.jocn.2026.111905_b0180","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78518","article-title":"Epidemiological characteristics and prevalence rates of research reproducibility across disciplines: a scoping review of articles published in 2018-2019","volume":"12","author":"Cobey","year":"2023","journal-title":"Elife"},{"issue":"11","key":"10.1016\/j.jocn.2026.111905_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002870","article-title":"Biomedical researchers\u2019 perspectives on the reproducibility of research","volume":"22","author":"Cobey","year":"2024","journal-title":"PLoS Biol"},{"issue":"12","key":"10.1016\/j.jocn.2026.111905_b0190","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrclinonc.2013.171","article-title":"Reproducibility of research and preclinical validation: problems and solutions","volume":"10","author":"Pusztai","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jocn.2026.111905_b0195","unstructured":"Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US | Health Policy | JAMA Health Forum | JAMA Network. Accessed August 15, 2025. https:\/\/jamanetwork.com\/journals\/jama-health-forum\/fullarticle\/2787276?utm_source=openevidence&utm_medium=referral."}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826000561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826000561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:53:44Z","timestamp":1772628824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586826000561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"alternative-id":["S0967586826000561"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.111905","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists and aneurysm rupture risk in type 2 diabetes: a multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.111905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111905"}}